News
Zacks.com on MSN2d
Merck Starts Phase III Studies on Once-Monthly Pill for HIV PreventionMRK launches Phase III trials for its once-monthly HIV prevention pill MK-8527, aiming to rival Gilead's daily PrEP options.
Zacks.com on MSN6d
FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV PillMRK's regulatory filing for once-daily HIV pill DOR/ISL gets FDA acceptance, with a decision expected by April 2026.
HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...
The new drug application is supported by 48-week data from the Phase III MK-8591A-051 and MK-8591A-052 trials, which showed ...
A monthly pill would add to the growing number of choices for HIV preexposure prophylaxis, which is now seen as the best hope ...
The FDA has accepted the New Drug Application for doravirine/islatravir for adults with virologically-suppressed HIV-1 infection.
President Trump said he was likely to impose tariffs on pharmaceuticals as soon as the end of the month, starting with a "low ...
Amarna Therapeutics and NorthX Biologics finalized an agreement to advance Nimvec AM510 gene therapy toward clinical trials for Type 1 Diabetes. Now in its fourth year, the MM+M Media Summit brings ...
AllAfrica on MSN3d
Momentum Builds For Long-Acting HIV Solutions As IAS 2025 Spotlights Scientific Progress, Funding Challenges And Leaders' Calls To ActionNew WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for long-acting injectable cabotegravir for treatment, and Merck’s once-monthly ...
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally ...
NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback